AMPA receptors in schizophrenia: A systematic review of postmortem studies on receptor subunit expression and binding
AMPA receptors in schizophrenia: A systematic review of postmortem studies on receptor subunit expression and binding
复制标题
DOI：
10.1016/j.schres.2022.02.033
复制
发表时间：
2022-03
影响因子：
4.5
通讯作者：
Kengo Yonezawa;H. Tani;S. Nakajima;Nobuhiro Nagai;T. Koizumi;Tomoyuki Miyazaki;Masaru Mimura;Takuya Takahashi;H. Uchida
中科院分区：
文献类型：
--
作者：
Kengo Yonezawa;H. Tani;S. Nakajima;Nobuhiro Nagai;T. Koizumi;Tomoyuki Miyazaki;Masaru Mimura;Takuya Takahashi;H. Uchida
研究背景虽然在精神分裂症的尸检研究中发现了α-氨基-3-羟基-5-甲基-4-异恶唑丙酸（AMPA）型受体表达的改变，但这些发现并不一致。因此，我们的目的是系统地回顾尸检研究，调查AMPA受体在精神分裂症的表达。MethodsA系统的文献检索进行尸检研究，测量AMPA受体亚基表达或受体结合在精神分裂症相比，健康人在2021年2月3日，使用Medline和Embase.ResultsA共39个相关的文章，确定从1360个初始报告。背外侧前额叶皮层（DLPFC）是研究最多的区域（15项研究），其次是内侧颞叶（8项研究）。对于DLPFC，4/15项研究（26.7%）显示精神分裂症患者与对照组相比AMPA受体结合或亚基表达增加，尤其是在GRIA 1和GRIA 4中，2/15项研究（13.3%）报告降低，尤其是在GRIA 2中，8/15项研究（56.7%）发现无显著差异。在6/8的研究（75.0%）中观察到的表达或受体结合的降低在海马的精神分裂症患者的亚区域相比，在对照组，而其他两项研究发现没有显着差异。这些结果在其他脑区不一致，这可能是由于该人群的异质性，各种研究设计，死后的生理变化以及研究数量有限。未来的体内研究有必要检查AMPA受体在人脑中的表达，以及它们的综合临床特征。
BackgroundWhile altered expression of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type receptor has been reported in postmortem studies of schizophrenia, these findings are inconsistent. Therefore, we aimed to systematically review postmortem studies that investigated AMPA receptor expressions in schizophrenia.MethodsA systematic literature search was conducted for postmortem studies that measured AMPA receptor subunit expressions or receptor bindings in schizophrenia compared to healthy individuals on February 3, 2021, using Medline and Embase.ResultsA total of 39 relevant articles were identified from 1360 initial reports. The dorsolateral prefrontal cortex (DLPFC) was the most investigated region (15 studies), followed by the medial temporal lobe (8 studies). For the DLPFC, 4/15 studies (26.7%) showed increased AMPA receptor binding or subunit expression in patients with schizophrenia compared to that in controls, especially in GRIA1 and GRIA4, 2/15 studies (13.3%) reported a decrease, particularly in GRIA2, and 8/15 studies (56.7%) found no significant differences. A decreased expression or receptor binding was observed in 6/8 studies (75.0%) in the subregions of the hippocampus in patients with schizophrenia compared to that in controls, whereas the other two studies found no significant differences.ConclusionPublished data have reported decreased subunit expression or receptor binding in the hippocampus in schizophrenia. These findings were inconsistent in other brain regions, which might be due to the heterogeneity of this population, various study design, physiological changes after death, and limited number of studies. Future in vivo studies are warranted to examine AMPA receptor expressions in human brains, together with their comprehensive clinical characterization.